Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia

Dinaciclib (SCH727965) is a selective CDKi chosen for clinical development based upon a favorable therapeutic index in cancer xenograft models. We performed a phase I dose escalation study of dinaciclib in relapsed and refractory CLL patients with intact organ function and WBC < 200 × 10(9)/L. Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Flynn, Joseph, Jones, Jeffrey, Johnson, Amy J., Andritsos, Leslie, Maddocks, Kami, Jaglowski, Samantha, Hessler, Joshua, Grever, Michael R., Ellie, Im, Zhou, Honghong, Zhu, Yali, Zhang, Da, Small, Karen, Bannerji, Rajat, Byrd, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551390/
https://www.ncbi.nlm.nih.gov/pubmed/25708835
http://dx.doi.org/10.1038/leu.2015.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551390/
https://www.ncbi.nlm.nih.gov/pubmed/25708835
http://dx.doi.org/10.1038/leu.2015.31

Ejemplares similares